Editorial: Oncolytic viruses: An approved product on the horizon?

Molecular Therapy

Volumn 18, Issue 2, 2010, Pages 233-234

  Bell, John ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPESVIRUS VECTOR; JK 594; ONCOLYTIC VIRUS; ONCOVEX; ONYX 015; PACLITAXEL; REOLYSIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

CANCER STAGING; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FEASIBILITY STUDY; HEAD AND NECK CANCER; HUMAN; LIVER CELL CARCINOMA; MELANOMA; ONCOLYTIC VIROTHERAPY; REOVIRUS; SIGNAL TRANSDUCTION; TREATMENT INDICATION; VIRUS CELL INTERACTION; VIRUS REPLICATION; BIOTECHNOLOGY;

BIOTECHNOLOGY; CLINICAL TRIALS AS TOPIC; ONCOLYTIC VIRUSES;

EID: 76249094706     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.314     Document Type: Editorial

References (8)

1. Nakamura, T, Peng, KW, Harvey, M, Greiner, S, Lorimer, IA, James, CD, et al. (2005). Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 23: 209-214.
2. Bartee, E and McFadden, G (2009). Human cancer cells have specifcally lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-β. Cytokine 47:199-205.
3. Power, AT and Bell, JC (2007). Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther 15: 660-665.
4. Ivy, P, Wick, JY and Kaufman, BM (2009). An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6:569-579.
5. Senzer, NN, Kaufman, HL, Amatruda, T, Nemunaitis, M, Reid, T, Daniels, G, et al. (2009). Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresect-able metastatic melanoma. J Clin Oncol 27:5763-5771.
6. Vidal, L, Pandha, HS, Yap, TA, White, CL, Twigger, K, Vile, RG, et al. (2008). A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 14:7127-7137.
7. Pandha, HS, Heinemann, L, Simpson, GR, Melcher, A, Prestwich, R, Errington, F, et al. (2009). Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res 15:6158-6166.
8. Park, BH, Hwang, T, Liu, TC, Sze, DY, Kim, JS, Kwon, HC, et al. (2008). Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 9:533-542.